Valeant rolls out prelim data on its newly purchased cancer vaccine Provenge

Valeant ($VRX) only just picked up Provenge from bankrupt Dendreon ($DNDN), but it's already trumpeting positive data for the flailing prostate cancer vaccine. According to preliminary results from a Phase II study, the immune response from Provenge continues two years after certain prostate cancer patients completed treatment. Dendreon exec Andrew Sandler called the data "very encouraging." Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.